University of Iowa Pharmaceuticals (UI Pharmaceuticals), a division of the University of Iowa College of Pharmacy, is actively involved in supporting the fight against COVID-19.  As part of these efforts, we are supporting Constant Therapeutics, LLC., by manufacturing clinical drug supplies of their investigational drug TXA127.  This drug candidate is being evaluated as a possible treatment for the symptoms of COVID-19 infection.  By prioritizing COVID-19 related projects we were able to manufacture and release the product for shipment within eight weeks of the active pharmaceutical ingredient (API) arriving at our facility.  TXA127 is a pharmaceutical formulation of the natural human peptide, angiotensin-(1-7). TXA127 is designed to restore angiotensin-(1-7) levels which are reduced in COVID-19 infected patients due to the inactivation of angiotensin-converting enzyme 2 (ACE2) by a virus. This restoration eventually leads to improved pulmonary function, which is one of the normal biologic effects of angiotensin-(1-7). UI Pharmaceuticals is proud to have been able to support this study by preparing the investigational drug supply.  We stand ready to collaborate with all our clients trying to accelerate their novel treatments into human clinical trials.  For more information on Constant Therapeutics, LLC. and their drug development projects go to:

http://www.constanttherapeutics.com/programs/

https://www.statnews.com/2020/06/10/coronavirus-lungs-enzyme/